US7192596B2
(en)
*
|
1996-08-23 |
2007-03-20 |
The Health Protection Agency Ipsen Limited |
Recombinant toxin fragments
|
GB9617671D0
(en)
|
1996-08-23 |
1996-10-02 |
Microbiological Res Authority |
Recombinant toxin fragments
|
US8012491B2
(en)
|
1996-08-23 |
2011-09-06 |
Syntaxin, Ltd. |
Recombinant toxin fragments
|
US8790897B2
(en)
*
|
1998-08-25 |
2014-07-29 |
Syntaxin Ltd. |
Treatment of mucus hypersecretion
|
US20040071736A1
(en)
*
|
1998-08-25 |
2004-04-15 |
Health Protection Agency |
Methods and compounds for the treatment of mucus hypersecretion
|
US7132259B1
(en)
*
|
1999-08-25 |
2006-11-07 |
Allergan, Inc. |
Activatable recombinant neurotoxins
|
US20090018081A1
(en)
*
|
1999-08-25 |
2009-01-15 |
Allergan, Inc. |
Activatable clostridial toxins
|
US7740868B2
(en)
|
1999-08-25 |
2010-06-22 |
Allergan, Inc. |
Activatable clostridial toxins
|
US20080032931A1
(en)
*
|
1999-08-25 |
2008-02-07 |
Steward Lance E |
Activatable clostridial toxins
|
GB9922554D0
(en)
*
|
1999-09-23 |
1999-11-24 |
Microbiological Res Authority |
Inhibition of secretion from non-neuronal cells
|
US7138127B1
(en)
*
|
2000-01-19 |
2006-11-21 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
US7273722B2
(en)
*
|
2000-11-29 |
2007-09-25 |
Allergan, Inc. |
Neurotoxins with enhanced target specificity
|
GB0111146D0
(en)
*
|
2001-05-04 |
2001-06-27 |
Imp College Innovations Ltd |
Methods
|
US7374896B2
(en)
*
|
2001-08-28 |
2008-05-20 |
Allergan, Inc. |
GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
|
US8022172B2
(en)
*
|
2001-08-28 |
2011-09-20 |
Allergan, Inc. |
Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
|
US7332567B2
(en)
*
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
US7022329B2
(en)
*
|
2002-02-25 |
2006-04-04 |
Allergan, Inc. |
Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
|
EP1531859A4
(de)
*
|
2002-05-31 |
2005-12-07 |
Univ Jefferson |
Zusammensetzungen und verfahren für den transepithelialen molekültransport
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8039587B2
(en)
|
2003-10-24 |
2011-10-18 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US7514088B2
(en)
|
2005-03-15 |
2009-04-07 |
Allergan, Inc. |
Multivalent Clostridial toxin derivatives and methods of their use
|
US7811584B2
(en)
*
|
2004-06-30 |
2010-10-12 |
Allergan, Inc. |
Multivalent clostridial toxins
|
AU2005279741B2
(en)
|
2004-09-01 |
2011-10-06 |
Allergan, Inc. |
Degradable clostridial toxins
|
DE102004043009A1
(de)
*
|
2004-09-06 |
2006-03-23 |
Toxogen Gmbh |
Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
|
WO2006068794A2
(en)
*
|
2004-11-22 |
2006-06-29 |
New York University |
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
|
US8603779B2
(en)
|
2004-12-01 |
2013-12-10 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
GB0426397D0
(en)
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
GB0426394D0
(en)
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
US8399400B2
(en)
|
2004-12-01 |
2013-03-19 |
Syntaxin, Ltd. |
Fusion proteins
|
US8778634B2
(en)
|
2004-12-01 |
2014-07-15 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
US7659092B2
(en)
|
2004-12-01 |
2010-02-09 |
Syntaxin, Ltd. |
Fusion proteins
|
US8512984B2
(en)
|
2004-12-01 |
2013-08-20 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
DE102005002978B4
(de)
*
|
2005-01-21 |
2013-04-25 |
Merz Pharma Gmbh & Co. Kgaa |
Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
|
AU2006225116B2
(en)
*
|
2005-03-15 |
2012-04-19 |
Allergan, Inc. |
Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
|
US8021859B2
(en)
|
2005-03-15 |
2011-09-20 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
DE102005019302A1
(de)
*
|
2005-04-26 |
2006-11-16 |
Toxogen Gmbh |
Carrier zum Targeting von Nervenzellen
|
WO2008008082A2
(en)
|
2005-09-19 |
2008-01-17 |
Allergan, Inc. |
Clostridial toxin activatable clostridial toxins
|
US8168206B1
(en)
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
EP2001902B1
(de)
|
2006-03-14 |
2013-03-27 |
Allergan, Inc. |
Modifizierte clostridiale toxine mit geänderten targeting-fähigkeiten für die target-zellen von clostridialem toxin
|
GB0610867D0
(en)
|
2006-06-01 |
2006-07-12 |
Syntaxin Ltd |
Treatment of pain
|
CA2658260A1
(en)
*
|
2006-07-11 |
2008-01-17 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
|
WO2008105901A2
(en)
*
|
2006-07-11 |
2008-09-04 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
|
CA2657521A1
(en)
|
2006-07-11 |
2008-01-17 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
|
JP2010500967A
(ja)
*
|
2006-07-20 |
2010-01-14 |
ザ ジェネラル ホスピタル コーポレイション |
コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
|
WO2011039584A2
(en)
*
|
2009-10-01 |
2011-04-07 |
Nikos Tsopanoglou |
Peptides
|
JP2011514308A
(ja)
*
|
2007-10-23 |
2011-05-06 |
アラーガン、インコーポレイテッド |
改変クロストリジウム毒素を用いる泌尿生殖器神経学的障害の治療方法
|
JP2011514307A
(ja)
*
|
2007-10-23 |
2011-05-06 |
アラーガン、インコーポレイテッド |
改変クロストリジウム毒素を用いる慢性神経性炎症の治療方法
|
CN102356091A
(zh)
|
2008-03-14 |
2012-02-15 |
阿勒根公司 |
基于免疫的血清型a肉毒杆菌毒素活性测定
|
KR101604515B1
(ko)
*
|
2008-03-14 |
2016-03-17 |
알러간, 인코포레이티드 |
면역-기반 보툴리눔 독소 세로타입 a 활성 검정
|
ES2614990T3
(es)
*
|
2008-06-12 |
2017-06-02 |
Ipsen Bioinnovation Limited |
Proteínas de fusión para uso en el tratamiento de acromegalia
|
US8796216B2
(en)
|
2008-06-12 |
2014-08-05 |
Syntaxin Limited |
Suppression of neuroendocrine diseases
|
US20100034853A1
(en)
*
|
2008-08-05 |
2010-02-11 |
Solstice Neurosciences, Inc. |
Compositions of activated botulinum toxin type B
|
US20100034854A1
(en)
*
|
2008-08-05 |
2010-02-11 |
Solstice Neurosciences, Inc. |
Compositions of activated botulinum holotoxin type B (150 KD)
|
US20100112006A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Solstice Neurosciences, Inc. |
Compositions of activated botulinum holotoxin type B (150 kD)
|
WO2010051039A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Solstice Neurosciences, Inc. |
Compositions of activated botulinum toxin type b
|
KR20110106346A
(ko)
|
2008-12-10 |
2011-09-28 |
알러간, 인코포레이티드 |
클로스트리디움 독소 약제학적 조성물
|
EP2202518A1
(de)
|
2008-12-19 |
2010-06-30 |
Merz Pharma GmbH & Co.KGaA |
In-Vivo-Assay zur Quantifizierung der clostridiellen Neurotoxinaktivität
|
US9492505B2
(en)
|
2009-01-21 |
2016-11-15 |
University Of Florida Research Foundation, Inc. |
Satiation peptide administration
|
EP2218783A1
(de)
|
2009-02-05 |
2010-08-18 |
Merz Pharma GmbH & Co. KGaA |
Neuartiges Verfahren zur Herstellung von Neurotoxinen
|
GB0903006D0
(en)
|
2009-02-23 |
2009-04-08 |
Syntaxin Ltd |
Modified non-cytotoxic proteases
|
SI2406371T1
(sl)
|
2009-03-13 |
2018-10-30 |
Allergan, Inc. |
Celice, koristne za teste aktivnosti botulinskega toksina serotipa a na podlagi imunologije
|
DK3281953T3
(da)
|
2009-03-13 |
2020-01-20 |
Allergan Inc |
Immun-baserede omdirigerede endopeptidase-aktivitetsassays
|
JP5689113B2
(ja)
*
|
2009-04-27 |
2015-03-25 |
メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー |
ニューロトキシンポリペプチドの量の測定とその触媒及びタンパク質分解活性の測定のための手段及び方法
|
CA2771298A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Allergan, Inc. |
Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
|
CA2771289A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Allergan, Inc. |
Methods of treating cancer using galanin retargeted endpeptidases
|
KR20120107926A
(ko)
*
|
2009-08-14 |
2012-10-04 |
알러간, 인코포레이티드 |
오피오이드 재표적화된 엔드펩티다아제를 사용하여 암을 치료하는 방법
|
WO2011041779A1
(en)
|
2009-10-02 |
2011-04-07 |
Allergan, Inc. |
In vitro method of determining changes in a protein environment
|
MX2012006985A
(es)
|
2009-12-16 |
2012-09-12 |
Allergan Inc |
Toxinas clostridium modificadas que comprenden un dominio de enlace al sitio de escision de la proteasa integrado.
|
PL2526200T3
(pl)
|
2010-01-22 |
2016-10-31 |
|
Test in vitro do oznaczania ilościowego aktywności neurotoksyny klostridialnej
|
JP5956350B2
(ja)
|
2010-01-25 |
2016-07-27 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
単鎖タンパク質をそれらの2鎖形態に細胞内変換する方法
|
WO2011091419A2
(en)
*
|
2010-01-25 |
2011-07-28 |
New York Universiy |
Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
|
US8989186B2
(en)
|
2010-06-08 |
2015-03-24 |
Brocade Communication Systems, Inc. |
Virtual port grouping for virtual cluster switching
|
US9461840B2
(en)
|
2010-06-02 |
2016-10-04 |
Brocade Communications Systems, Inc. |
Port profile management for virtual cluster switching
|
US9716672B2
(en)
|
2010-05-28 |
2017-07-25 |
Brocade Communications Systems, Inc. |
Distributed configuration management for virtual cluster switching
|
US9001824B2
(en)
|
2010-05-18 |
2015-04-07 |
Brocade Communication Systems, Inc. |
Fabric formation for virtual cluster switching
|
US8867552B2
(en)
|
2010-05-03 |
2014-10-21 |
Brocade Communications Systems, Inc. |
Virtual cluster switching
|
US9270486B2
(en)
|
2010-06-07 |
2016-02-23 |
Brocade Communications Systems, Inc. |
Name services for virtual cluster switching
|
MX369263B
(es)
|
2010-05-20 |
2019-11-04 |
Allergan Inc |
Toxinas de clostridium degradables.
|
US9246703B2
(en)
|
2010-06-08 |
2016-01-26 |
Brocade Communications Systems, Inc. |
Remote port mirroring
|
US9628293B2
(en)
|
2010-06-08 |
2017-04-18 |
Brocade Communications Systems, Inc. |
Network layer multicasting in trill networks
|
US9608833B2
(en)
|
2010-06-08 |
2017-03-28 |
Brocade Communications Systems, Inc. |
Supporting multiple multicast trees in trill networks
|
US9807031B2
(en)
|
2010-07-16 |
2017-10-31 |
Brocade Communications Systems, Inc. |
System and method for network configuration
|
EP2603518B1
(de)
*
|
2010-08-11 |
2015-06-17 |
Merz Pharma GmbH & Co. KGaA |
Selektive herstellung von rekombinanten neurotoxin-polypeptiden
|
US20130330369A1
(en)
|
2010-10-08 |
2013-12-12 |
Allergan, Inc. |
Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
|
WO2012051447A1
(en)
|
2010-10-14 |
2012-04-19 |
Allergan, Inc. |
Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
|
US20120207734A1
(en)
*
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
|
WO2012112434A1
(en)
*
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Inhibiting aberrant blood vessel formation using retargeted endopeptidases
|
WO2012112420A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Treatments using psma ligand endopeptidases
|
US20120244188A1
(en)
|
2011-03-25 |
2012-09-27 |
Allergan, Inc. |
Treatment of Sensory Disturbance Disorders
|
US20120251575A1
(en)
|
2011-03-28 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase Treatment of Involuntary Movement Disorders
|
US20120251573A1
(en)
|
2011-03-28 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase Treatment of Neuroendocrine Disorders
|
US20120251574A1
(en)
|
2011-03-28 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
|
US20120258132A1
(en)
|
2011-03-29 |
2012-10-11 |
Allergan, Inc. |
Vagal Nerve-Based Disorders
|
US20120251518A1
(en)
|
2011-03-29 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase Treatment of Sexual Dysfunction Disorders
|
US20120251515A1
(en)
|
2011-03-29 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase Treatment of Cosmesis Disorders
|
US20120251519A1
(en)
|
2011-03-29 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase Treatment of Smooth Muscle Disorders
|
US9270572B2
(en)
|
2011-05-02 |
2016-02-23 |
Brocade Communications Systems Inc. |
Layer-3 support in TRILL networks
|
US9764009B2
(en)
|
2011-06-13 |
2017-09-19 |
Allergan, Inc. |
Treatment of psychological trauma
|
US9401861B2
(en)
|
2011-06-28 |
2016-07-26 |
Brocade Communications Systems, Inc. |
Scalable MAC address distribution in an Ethernet fabric switch
|
US9407533B2
(en)
|
2011-06-28 |
2016-08-02 |
Brocade Communications Systems, Inc. |
Multicast in a trill network
|
US8948056B2
(en)
|
2011-06-28 |
2015-02-03 |
Brocade Communication Systems, Inc. |
Spanning-tree based loop detection for an ethernet fabric switch
|
US8885641B2
(en)
|
2011-06-30 |
2014-11-11 |
Brocade Communication Systems, Inc. |
Efficient trill forwarding
|
US9736085B2
(en)
|
2011-08-29 |
2017-08-15 |
Brocade Communications Systems, Inc. |
End-to end lossless Ethernet in Ethernet fabric
|
US9699117B2
(en)
|
2011-11-08 |
2017-07-04 |
Brocade Communications Systems, Inc. |
Integrated fibre channel support in an ethernet fabric switch
|
US9450870B2
(en)
|
2011-11-10 |
2016-09-20 |
Brocade Communications Systems, Inc. |
System and method for flow management in software-defined networks
|
EP2793934B1
(de)
|
2011-12-23 |
2017-08-23 |
Merz Pharma GmbH & Co. KGaA |
Neuartiges verfahren zur herstellung von di-ketten-proteinen zur verwendung bei menschen
|
US20130171122A1
(en)
|
2011-12-29 |
2013-07-04 |
Allergan, Inc. |
Endopeptidase and neurotoxin combination treatment of bladder disorders
|
US10451621B2
(en)
|
2011-12-31 |
2019-10-22 |
Allergan, Inc. |
Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
|
US8995272B2
(en)
|
2012-01-26 |
2015-03-31 |
Brocade Communication Systems, Inc. |
Link aggregation in software-defined networks
|
US9742693B2
(en)
|
2012-02-27 |
2017-08-22 |
Brocade Communications Systems, Inc. |
Dynamic service insertion in a fabric switch
|
US9154416B2
(en)
|
2012-03-22 |
2015-10-06 |
Brocade Communications Systems, Inc. |
Overlay tunnel in a fabric switch
|
US9374301B2
(en)
|
2012-05-18 |
2016-06-21 |
Brocade Communications Systems, Inc. |
Network feedback in software-defined networks
|
US10277464B2
(en)
|
2012-05-22 |
2019-04-30 |
Arris Enterprises Llc |
Client auto-configuration in a multi-switch link aggregation
|
EP2853066B1
(de)
|
2012-05-23 |
2017-02-22 |
Brocade Communications Systems, Inc. |
Layer-3-überlagerungs-gateways
|
US9602430B2
(en)
|
2012-08-21 |
2017-03-21 |
Brocade Communications Systems, Inc. |
Global VLANs for fabric switches
|
US20140056870A1
(en)
|
2012-08-27 |
2014-02-27 |
Allergan, Inc. |
Fusion proteins
|
US9005628B2
(en)
*
|
2012-10-04 |
2015-04-14 |
Dublin City University |
Biotherapy for pain
|
WO2014066916A2
(en)
|
2012-10-28 |
2014-05-01 |
Revance Therapeutics, Inc. |
Compositions and methods for safe treatment of rhinitis
|
GB201219602D0
(en)
|
2012-10-31 |
2012-12-12 |
Syntaxin Ltd |
Recombinant clostridium botulinum neurotoxins
|
US9401872B2
(en)
|
2012-11-16 |
2016-07-26 |
Brocade Communications Systems, Inc. |
Virtual link aggregations across multiple fabric switches
|
RU2673910C2
(ru)
*
|
2012-11-21 |
2018-12-03 |
Ипсен Байоинновейшн Лимитед |
Способ производства протеолитически процессированного полипептида
|
EP2934571B1
(de)
|
2012-12-18 |
2018-05-30 |
Allergan, Inc. |
Prophylaktische behandlung von herpesrezidiven
|
US9548926B2
(en)
|
2013-01-11 |
2017-01-17 |
Brocade Communications Systems, Inc. |
Multicast traffic load balancing over virtual link aggregation
|
US9350680B2
(en)
|
2013-01-11 |
2016-05-24 |
Brocade Communications Systems, Inc. |
Protection switching over a virtual link aggregation
|
US9413691B2
(en)
|
2013-01-11 |
2016-08-09 |
Brocade Communications Systems, Inc. |
MAC address synchronization in a fabric switch
|
US9565113B2
(en)
|
2013-01-15 |
2017-02-07 |
Brocade Communications Systems, Inc. |
Adaptive link aggregation and virtual link aggregation
|
US9315549B2
(en)
|
2013-01-28 |
2016-04-19 |
New York University |
Treatment methods using atoxic neurotoxin derivatives
|
US9565099B2
(en)
|
2013-03-01 |
2017-02-07 |
Brocade Communications Systems, Inc. |
Spanning tree in fabric switches
|
US9401818B2
(en)
|
2013-03-15 |
2016-07-26 |
Brocade Communications Systems, Inc. |
Scalable gateways for a fabric switch
|
US9565028B2
(en)
|
2013-06-10 |
2017-02-07 |
Brocade Communications Systems, Inc. |
Ingress switch multicast distribution in a fabric switch
|
US9699001B2
(en)
|
2013-06-10 |
2017-07-04 |
Brocade Communications Systems, Inc. |
Scalable and segregated network virtualization
|
GB201312317D0
(en)
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
US9806949B2
(en)
|
2013-09-06 |
2017-10-31 |
Brocade Communications Systems, Inc. |
Transparent interconnection of Ethernet fabric switches
|
US9912612B2
(en)
|
2013-10-28 |
2018-03-06 |
Brocade Communications Systems LLC |
Extended ethernet fabric switches
|
US9216210B2
(en)
*
|
2013-12-23 |
2015-12-22 |
Dublin City University |
Multiprotease therapeutics for chronic pain
|
US9548873B2
(en)
|
2014-02-10 |
2017-01-17 |
Brocade Communications Systems, Inc. |
Virtual extensible LAN tunnel keepalives
|
US9975929B2
(en)
|
2014-03-05 |
2018-05-22 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
US10581758B2
(en)
|
2014-03-19 |
2020-03-03 |
Avago Technologies International Sales Pte. Limited |
Distributed hot standby links for vLAG
|
US10476698B2
(en)
|
2014-03-20 |
2019-11-12 |
Avago Technologies International Sales Pte. Limited |
Redundent virtual link aggregation group
|
US10063473B2
(en)
|
2014-04-30 |
2018-08-28 |
Brocade Communications Systems LLC |
Method and system for facilitating switch virtualization in a network of interconnected switches
|
EP3760186A1
(de)
|
2014-04-30 |
2021-01-06 |
Allergan, Inc. |
Formulierungen von biologischen stoffen zur intravesikalen instillation
|
US9800471B2
(en)
|
2014-05-13 |
2017-10-24 |
Brocade Communications Systems, Inc. |
Network extension groups of global VLANs in a fabric switch
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
US10616108B2
(en)
|
2014-07-29 |
2020-04-07 |
Avago Technologies International Sales Pte. Limited |
Scalable MAC address virtualization
|
JP6585157B2
(ja)
|
2014-07-31 |
2019-10-02 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
膀胱内注入用の生物製剤の処方
|
US9544219B2
(en)
|
2014-07-31 |
2017-01-10 |
Brocade Communications Systems, Inc. |
Global VLAN services
|
US9807007B2
(en)
|
2014-08-11 |
2017-10-31 |
Brocade Communications Systems, Inc. |
Progressive MAC address learning
|
US9524173B2
(en)
|
2014-10-09 |
2016-12-20 |
Brocade Communications Systems, Inc. |
Fast reboot for a switch
|
US9699029B2
(en)
|
2014-10-10 |
2017-07-04 |
Brocade Communications Systems, Inc. |
Distributed configuration management in a switch group
|
WO2016094555A1
(en)
|
2014-12-09 |
2016-06-16 |
New York University |
Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
|
US10900955B2
(en)
|
2014-12-19 |
2021-01-26 |
Merz Pharma Gmbh & Co. Kgaa |
Means and methods for the determination of the biological activity of BoNT/E in cells
|
US9626255B2
(en)
|
2014-12-31 |
2017-04-18 |
Brocade Communications Systems, Inc. |
Online restoration of a switch snapshot
|
US9628407B2
(en)
|
2014-12-31 |
2017-04-18 |
Brocade Communications Systems, Inc. |
Multiple software versions in a switch group
|
US9942097B2
(en)
|
2015-01-05 |
2018-04-10 |
Brocade Communications Systems LLC |
Power management in a network of interconnected switches
|
US10003552B2
(en)
|
2015-01-05 |
2018-06-19 |
Brocade Communications Systems, Llc. |
Distributed bidirectional forwarding detection protocol (D-BFD) for cluster of interconnected switches
|
PL3242884T3
(pl)
|
2015-01-09 |
2021-08-16 |
Ipsen Bioinnovation Limited |
Kationowe neurotoksyny
|
TWI704156B
(zh)
*
|
2015-03-04 |
2020-09-11 |
德商曼茲法瑪股份有限公司 |
用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
|
US9807005B2
(en)
|
2015-03-17 |
2017-10-31 |
Brocade Communications Systems, Inc. |
Multi-fabric manager
|
US10038592B2
(en)
|
2015-03-17 |
2018-07-31 |
Brocade Communications Systems LLC |
Identifier assignment to a new switch in a switch group
|
US10579406B2
(en)
|
2015-04-08 |
2020-03-03 |
Avago Technologies International Sales Pte. Limited |
Dynamic orchestration of overlay tunnels
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
US10439929B2
(en)
|
2015-07-31 |
2019-10-08 |
Avago Technologies International Sales Pte. Limited |
Graceful recovery of a multicast-enabled switch
|
BR112018003794A2
(pt)
*
|
2015-08-27 |
2018-09-25 |
Massachusetts Inst Technology |
composições e métodos para o tratamento da dor
|
US10171303B2
(en)
|
2015-09-16 |
2019-01-01 |
Avago Technologies International Sales Pte. Limited |
IP-based interconnection of switches with a logical chassis
|
GB201517450D0
(en)
|
2015-10-02 |
2015-11-18 |
Ipsen Biopharm Ltd |
Method
|
US9912614B2
(en)
|
2015-12-07 |
2018-03-06 |
Brocade Communications Systems LLC |
Interconnection of switches based on hierarchical overlay tunneling
|
WO2017125487A1
(en)
|
2016-01-20 |
2017-07-27 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
US11311633B2
(en)
|
2016-04-16 |
2022-04-26 |
University Of Florida Research Foundation, Incorporated |
Satiation peptides for weight loss and altered taste sensitivity
|
EP3263710A1
(de)
*
|
2016-07-01 |
2018-01-03 |
Ipsen Biopharm Limited |
Herstellung von aktivierten clostridien-neurotoxinen
|
EP3504226A1
(de)
*
|
2016-08-24 |
2019-07-03 |
President and Fellows of Harvard College |
Manipuliertes botulinumneurotoxin
|
EP3290437A1
(de)
|
2016-08-31 |
2018-03-07 |
Merz Pharma GmbH & Co. KGaA |
Neuartige rekombinante clostridienneurotoxine mit verkürzter wirkungsdauer
|
US10369190B2
(en)
|
2016-09-13 |
2019-08-06 |
Allergan, Inc. |
Non-protein clostridial toxin compositions
|
EP3312193A1
(de)
|
2016-10-19 |
2018-04-25 |
Merz Pharma GmbH & Co. KGaA |
Neuartige rekombinante botulinumneurotoxine mit beschleunigter wirkung
|
EP3333179A1
(de)
|
2016-12-07 |
2018-06-13 |
Merz Pharma GmbH & Co. KGaA |
Neuartiges rekombinantes botulinumneurotoxin mit beschleunigtem wirkungseintritt
|
EP3335719A1
(de)
|
2016-12-14 |
2018-06-20 |
Merz Pharma GmbH & Co. KGaA |
Neuartige rekombinante botulinumneurotoxine mit einer stabilisierten leichten kette
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
|
US11155802B2
(en)
|
2017-07-06 |
2021-10-26 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant botulinum neurotoxins with increased duration of effect
|
US20210008156A1
(en)
|
2017-10-26 |
2021-01-14 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
US20200354706A1
(en)
|
2017-11-22 |
2020-11-12 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
EP3723784A4
(de)
*
|
2017-12-15 |
2022-01-12 |
The Medical College of Wisconsin, Inc. |
Modifizierte clostridienneurotoxine als impfstoffe und konjugatimpfstoffplattformen
|
CN112351992A
(zh)
|
2017-12-20 |
2021-02-09 |
阿勒根公司 |
肉毒杆菌毒素细胞结合结构域多肽及其用于皮肤再生的方法
|
WO2019243376A1
(en)
|
2018-06-18 |
2019-12-26 |
Ipsen Biopharm Limited |
Intramuscular injection of botulinum toxin for the treatment of vulvodynia
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|
GB201815844D0
(en)
|
2018-09-28 |
2018-11-14 |
Ipsen Biopharm Ltd |
Therapeutic & comestic uses of botulinum neurotoxin serotype e
|
US20220357314A1
(en)
|
2018-09-28 |
2022-11-10 |
Ipsen Biopharm Limited |
Cell-based Clostridal Neurotoxin Assays
|
GB201900621D0
(en)
|
2019-01-16 |
2019-03-06 |
Ipsen Biopharm Ltd |
Labelled polypeptides
|
GB201907016D0
(en)
|
2019-05-17 |
2019-07-03 |
Ipsen Biopharm Ltd |
Screening method to determine suitability for participation in a clinical trial
|
GB201914034D0
(en)
|
2019-09-30 |
2019-11-13 |
Ipsen Biopharm Ltd |
Treatment of neurological disorders
|
GB202001353D0
(en)
|
2020-01-31 |
2020-03-18 |
Ipsen Biopharm Ltd |
Treatment of skin conditions
|
GB202100566D0
(en)
|
2021-01-15 |
2021-03-03 |
Ipsen Biopharm Ltd |
Treatment of brain damage
|
CN114957482A
(zh)
*
|
2021-02-26 |
2022-08-30 |
重庆誉颜制药有限公司 |
一种经修饰的神经毒素的单链多肽及其用途
|
GB202103372D0
(en)
|
2021-03-11 |
2021-04-28 |
Ipsen Biopharm Ltd |
Modified clostridial neurotoxins
|
GB202104294D0
(en)
|
2021-03-26 |
2021-05-12 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an exogenous activation loop
|
BR112023018473A2
(pt)
|
2021-03-30 |
2023-11-14 |
Ipsen Biopharm Ltd |
Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
|
EP4313120A1
(de)
|
2021-03-30 |
2024-02-07 |
Ipsen Biopharm Limited |
Behandlung von schmerzen und entzündlichen erkrankungen
|
GB202116795D0
(en)
|
2021-11-22 |
2022-01-05 |
Ipsen Biopharm Ltd |
Treatment of visceral pain
|
WO2023105289A1
(en)
|
2021-12-06 |
2023-06-15 |
Dublin City University |
Methods and compositions for the treatment of pain
|
TW202339791A
(zh)
*
|
2022-04-01 |
2023-10-16 |
大陸商重慶譽顏製藥有限公司 |
一種肉毒毒素蛋白組合物、製備方法及其應用
|
GB202213479D0
(en)
|
2022-09-14 |
2022-10-26 |
Ipsen Biopharm Ltd |
Cell-free clostridial neurotoxin assays
|
CN116063535B
(zh)
*
|
2022-09-14 |
2023-09-26 |
北京市疾病预防控制中心 |
一种抗体或其抗原结合片段及其制备方法和应用
|
GB202214232D0
(en)
|
2022-09-28 |
2022-11-09 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising an activating exogenous protease cleavage site
|
GB202214229D0
(en)
|
2022-09-28 |
2022-11-09 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an activating endosomal protease cleavage site
|
WO2024069191A1
(en)
|
2022-09-30 |
2024-04-04 |
Ipsen Biopharm Limited |
Clostridial neurotoxin for use in a treatment of bladder pain syndrome
|